These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34792037)

  • 1. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
    Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
    AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
    Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
    Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of diagnostic performance of radiologist- and AI-based assessments of T2-FLAIR mismatch sign and quantitative assessment using synthetic MRI in the differential diagnosis between astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Yuhei S; Fujioka Y; Narutomi F; Obara M; Yoshimoto K; Ishigami K
    Neuroradiology; 2024 Mar; 66(3):333-341. PubMed ID: 38224343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
    van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
    AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
    Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
    Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of T2-FLAIR discordance across a cohort of adult-type diffuse gliomas and deviations from the classic T2-FLAIR mismatch sign.
    Malik P; Soliman R; Chen YA; Munoz DG; Das S; Bharatha A; Mathur S
    Neuroradiology; 2024 Apr; 66(4):521-530. PubMed ID: 38347151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Jain R; Johnson DR; Patel SH; Castillo M; Smits M; van den Bent MJ; Chi AS; Cahill DP
    Neuro Oncol; 2020 Jul; 22(7):936-943. PubMed ID: 32064507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolution.
    Throckmorton P; Graber JJ
    Neurology; 2020 Sep; 95(11):e1582-e1589. PubMed ID: 32690782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.
    Kikuchi K; Togao O; Yamashita K; Momosaka D; Kikuchi Y; Kuga D; Hata N; Mizoguchi M; Yamamoto H; Iwaki T; Hiwatashi A; Ishigami K
    Sci Rep; 2022 Jun; 12(1):9197. PubMed ID: 35654812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric MRI and T2/FLAIR mismatch complements the World Health Organization 2021 classification for the diagnosis of IDH-mutant 1p/19q non-co-deleted/ATRX-mutant astrocytoma.
    Sawlani V; Jen JP; Patel M; Jain M; Haq H; Ughratdar I; Wykes V; Nagaraju S; Watts C; Pohl U
    Clin Radiol; 2024 Mar; 79(3):197-204. PubMed ID: 38101998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T
    Kinoshita M; Uchikoshi M; Sakai M; Kanemura Y; Kishima H; Nakanishi K
    Magn Reson Med Sci; 2021 Mar; 20(1):119-123. PubMed ID: 32101817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR textural analysis on T
    Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
    J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
    Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
    Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.